Filtered By:
Vaccination: Hepatitis Vaccine

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 4975 results found since Jan 2013.

Dissolving Microneedle Arrays as a Hepatitis B Vaccine Delivery System Adjuvanted by APC-Targeted Poly (Lactic-co-Glycolic Acid) (PLGA) Nanoparticles
This study verifies the feasibility of soluble composited microneedles administration in hepatitis B immunization, and provides new ideas for the development and application of non-injectable vaccine delivery systems.PMID:36697935 | DOI:10.1208/s12249-022-02473-9
Source: AAPS PharmSciTech - January 25, 2023 Category: Drugs & Pharmacology Authors: Xiaoling Zheng Jiahuan Zhu Caihong Zheng Zeng Tan Zhonghua Ji Jin Tao Yunchun Zhao Zhuwa Ji Ying Hu Source Type: research

The enhanced immune response of hepatitis B virus DNA vaccine using SiO2@LDH nanoparticles as an adjuvant.
Abstract Various approaches have been used to improve systemic immune response to infectious disease or virus, and DNA vaccination has been demonstrated to be one of these effective ways to elicit protective immunity against pathogens. Our previous studies showed that layered double hydroxides (LDH) nanoparticles could be efficiently taken up by the MDDCs and had an adjuvant activity for DC maturation. To further enhance the immune adjuvant activity of LDH, core-shell structure SiO2@LDH nanoparticles were synthesized with an average diameter of about 210 nm. And its high transfection efficiency in vitro was demo...
Source: Biomaterials - October 4, 2013 Category: Materials Science Authors: Wang J, Zhu R, Gao B, Wu B, Li K, Sun X, Liu H, Wang S Tags: Biomaterials Source Type: research

Therapeutic application of nanoparticles in hepatitis diseases: a narrative review 2011-2021
Curr Pharm Biotechnol. 2022 Jul 27. doi: 10.2174/1389201023666220727141624. Online ahead of print.ABSTRACTPURPOSE: Hepatitis, an inflammation of the liver parenchyma, is a viral disease. Addressing the challenges of hepatitis is very important. Therefore, using nanoparticles (NPs) in solving the problems of hepatitis diagnosis and treatment can be considered as a promising approach. Novelty: To the best of our knowledge, there are few studies to review the most widely used and effective NPs in the field of hepatitis. A literature review was performed on the publications available on the subject matter from 2011 to 2021. Th...
Source: Current Pharmaceutical Biotechnology - July 27, 2022 Category: Biotechnology Authors: Tahereh Zadeh Mehrizi Mehdi Shafiee Ardestani Source Type: research

Development and physicochemical, toxicity and immunogenicity assessments of recombinant hepatitis B surface antigen (rHBsAg) entrapped in chitosan and mannosylated chitosan nanoparticles: as a novel vaccine delivery system and adjuvant.
In this study chitosan nanoparticles (CS NPs) and mannosylated chitosan nanoparticles (MCH NPs) loaded with recombinant hepatitis B surface antigen (rHBsAg) was synthesized as a vaccine delivery system and assessed toxically and immunologically. The physicochemical properties of the nanoparticles (NPs) were determined by methods including scanning electron microscope (SEM) and dynamic light scattering (DLS). The morphology of the NPs was semi spherical and the average diameter of the loaded CS and MCH NPs was found to be 189 and 239 nm, respectively. The release studies showed that after the initial burst, both of the lo...
Source: Artificial Cells, Nanomedicine and Biotechnology - December 22, 2017 Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research

Hepatitis B Antigen Loaded Biodegradable Polymeric Nanoparticles: Formulation Optimization and In-vivo Immunization in BALB/c Mice.
Abstract The incredibly serious problem of Hepatitis B is virus-related chronic liver disease. The conventional preventive treatment of Hepatitis B requires booster dose, which requires repeated administration of the vaccine to the subject. Thus, there is a need to develop a formulation which can eliminate the need of frequent dosing and enhance patient's acquiescence. To prepare single dose nanovaccine of HBsAg by utilizing central composite design for optimization and interaction of independent variables effects on measured response. Nanovaccines were characterized for particle size, morphology, integrity, inter...
Source: Current Drug Delivery - June 3, 2018 Category: Drugs & Pharmacology Authors: Dewangan HK, Singh S, Maurya L, Srivastava A Tags: Curr Drug Deliv Source Type: research

Alginate-coated chitosan nanoparticles act as effective adjuvant for hepatitis A vaccine in mice.
Abstract The numerous recent hepatitis A outbreaks emphasize the need for vaccination; despite the effectiveness of the current ones, developments are needed to overcome its high cost plus some immune response limitations. Our study aims to evaluate the use of chitosan and alginate-coated chitosan nanoparticles as an adjuvant/carrier for the hepatitis A vaccine (HAV) against the traditional adjuvant alum. Immune responses towards (HAV-Al) with alum, (HAV-Ch) with chitosan, and (HAV-aCNP) with alginate-coated chitosan nanoparticles, were assessed in mice. HAV-aCNP significantly improved the immunogenicity by increa...
Source: International Journal of Biological Macromolecules - February 26, 2020 Category: Biochemistry Authors: AbdelAllah NH, Gaber Y, Abou-Taleb HA, Rashed ME, Azmy AF, AbdelGhani S Tags: Int J Biol Macromol Source Type: research

Immunological evaluation of colonic delivered Hepatitis B surface antigen loaded TLR-4 agonist modified solid fat nanoparticles.
This study supports that delivery of HBsAg to the colon may open new vista in designing oral vaccines later being one of most accepted route for potential vaccines in future. PMID: 27526270 [PubMed - as supplied by publisher]
Source: International Immunopharmacology - August 11, 2016 Category: Allergy & Immunology Authors: Sahu KK, Pandey RS Tags: Int Immunopharmacol Source Type: research

Protein Nanoparticles for Antigen Display in Vaccines
The technology relates to a protein-based nanoparticle platform that allows presentation of immunogenic molecules such as influenza virus antigens. This protein platform is made up of hepatitis B capsid/core proteins. The core proteins contain immunogenic loop c/e1, where other antigens can be inserted and the chimeric protein retains the ability to form capsid-like particles. The technology describes the insertion of one or more copies of influenza epitopes derived from the globular head or the stem region of hemagglutinin protein into or around the c/e1 loop of the core protein. The nanoparticles formed by the use of Hep...
Source: NIH OTT Licensing Opportunities - March 9, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research

Lipopolysaccharide derived alginate coated Hepatitis B antigen loaded chitosan nanoparticles for oral mucosal immunization.
The objective of the present study was to prepare and characterize alginate coated chitosan nanoparticles (ACNPs) loaded with HBsAg as an antigen to produce immunity; additionally anchored with lipopolysaccharide (LPS) as an adjuvant. Ionic gelation method was used to prepare chitosan nanoparticles (CNPs) which were loaded with HBsAg and stabilized by alginate coating to protect from gastric environment. Results showed that the prepared LPS-HB-ACNPs were small and spherical with mean particle size 605.23 nm, polydispersity index 0.234 and Zeta potential -26.2 mV and could effectively protect antigen at GIT in acidic me...
Source: International Journal of Biological Macromolecules - March 15, 2020 Category: Biochemistry Authors: Saraf S, Jain S, Sahoo RN, Mallick S Tags: Int J Biol Macromol Source Type: research

Protein Nanoparticles for Antigen Display in Vaccines
The technology relates to a protein-based nanoparticle platform that allows presentation of immunogenic molecules such as influenza virus antigens. This protein platform is made up of hepatitis B capsid/core proteins. The core proteins contain immunogenic loop c/e1, where other antigens can be inserted and the chimeric protein retains the ability to form capsid-like particles. The technology describes the insertion of one or more copies of influenza epitopes derived from the globular head or the stem region of hemagglutinin protein into or around the c/e1 loop of the core protein. The nanoparticles formed by the use of Hep...
Source: NIH OTT Licensing Opportunities - July 6, 2020 Category: Research Authors: ott-admin Source Type: research

Development and Characterization of Surface Modified PLGA Nanoparticles for Nasal Vaccine Delivery: Effect of Mucoadhesive Coating on Antigen Uptake and Immune Adjuvant Activity.
In conclusion, GC-PLGA NPs could be a promising carrier adjuvant for the nasal vaccine delivery for inducing a potent immune response at mucosal surface(s) and systemic circulation. PMID: 23831265 [PubMed - as supplied by publisher]
Source: European Journal of Pharmaceutics and Biopharmaceutics - July 3, 2013 Category: Drugs & Pharmacology Authors: Pawar D, Mangal S, Goswami R, Jaganathan K Tags: Eur J Pharm Biopharm Source Type: research